ClinicalTrials.gg
TerminatedNCT06736509Updated Jun 25, 2026Results posted

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

A Phase 3 interventional study of AXS-05 (dextromethorphan-bupropion) in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation, Psychomotor, sponsored by Axsome Therapeutics, Inc.. Terminated at 22 sites in 2 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study AXS-05-AD-305 was terminated due to completion of overall program objectives.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
558th of 1,609
139 · median 73
Started
2024
with 113 others
Phase 3
188 of 1,940
19 open now
Registered
1,770th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 558th largest by enrollment of the 1,609 interventional ones that give a count, is one of 114 that started in 2024, is one of 188 in phase 3, and was the 1,770th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this open-label extension trial was to evaluate the long-term safety of AXS-05 for the treatment of Alzheimer's disease agitation in subjects that participated in ADVANCE-2 or ACCORD-2.

Read the detailed description

This was a multi-center, open-label extension trial to evaluate the long-term safety of AXS-05 in subjects with Alzheimer's disease (AD) agitation that continued to receive AXS-05 given completion of ADVANCE-2 (AXS-05-AD-304) or ACCORD-2 (AXS-05-AD-303).

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation, Psychomotor

Keywords

  • AD Agitation
  • AXS-05
  • NMDA receptor antagonist
  • dextromethorphan
  • bupropion
  • Axsome
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the treatment period in Study AXS-05-AD-304 or exited from Study AXS-05-AD-303 due to study completion.
  • Caregiver is willing to communicate with site personnel, comply with all required study procedures, and oversee administration and compliance with the subject's study treatment.

Exclusion criteria

Exclusion Criteria:

  • Caregiver is unwilling or unable, in the opinion of the Investigator, to comply with study instructions.
  • Subject is hospitalized in a mental health facility (e.g., psychiatric hospital or ward), living in a nursing home, or living alone.
  • Any concurrent medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or endanger the subject's well-being.
  • Initiation of a new medication since enrolling in AXS-05-AD-304 and/or AXS-05-AD-303 which may pose a safety risk when taken concurrently with AXS-05.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Open-Label

    Experimental: AXS-05 (dextromethorphan-bupropion) up to 25 weeks

    Drug: AXS-05 (dextromethorphan-bupropion)

Interventions

06

What researchers measure

Primary outcomes

  1. Long-Term Safety

    Incidence of treatment-emergent adverse events following dosing with AXS-05

    Time frame: Up to 25 weeks

07

Results

Posted Jun 25, 2026

Participant flow

Participant flow — Overall Study
MilestoneOpen-Label
Started139
Completed0
Not completed139
Withdrew: Study terminated by sponsor137
Withdrew: Withdrawal by subject1
Withdrew: Other1

Outcome measures

PrimaryLong-Term Safety

Incidence of treatment-emergent adverse events following dosing with AXS-05

Time frame:
Up to 25 weeks
Reported as:
Count of participants · Participants
Long-Term Safety
ParticipantsOpen-Label
Subjects with any TEAEs16
Subjects with suspected to be drug-related TEAEs7
Subjects with serious TEAEs0
Subjects with TEAEs that led to drug withdrawal0
Subjects with TEAEs that led to study discontinuation0
Subjects with TEAEs that resulted in death0
Subjects with no TEAEs116

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were collected after administration of study drug through 7 days after the last dose (up to 25 weeks).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-Label0/139 (0%)0/139 (0%)16/139 (11.5%)
Most frequent other events
Most frequent other events
EventOpen-Label
HyperkalaemiaMetabolism and nutrition disorders4/139
HeadacheNervous system disorders4/139
DiarrhoeaGastrointestinal disorders3/139
InfluenzaInfections and infestations2/139
SomnolenceNervous system disorders2/139
TremorNervous system disorders2/139

Baseline characteristics

Age, Continuous
Age, Continuous(years)Open-Label
Mean74.3 ± 5.31
Sex: Female, Male
Sex: Female, Male(Participants)Open-Label
Female95
Male44
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Open-Label
Black or African American14
White124
Other1
08

Study locations

22 sites
  • Clinical Research Site
    Peoria, Arizona 85381, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    Bonita Springs, Florida 34134, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site
    Greenacres City, Florida 33467, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Miami, Florida 33126, United States
  • Clinical Research Site
    Miami, Florida 33145, United States
  • Clinical Research Site
    Miami, Florida 33155, United States
  • Clinical Research Site
    Miami, Florida 33165, United States
  • Clinical Research Site
    Miami, Florida 33173, United States
  • Clinical Research Site
    Miami Gardens, Florida 33014, United States
  • Clinical Research Site
    Miami Lakes, Florida 33014, United States
  • Clinical Research Site
    Pembroke Pines, Florida 33025, United States
  • Clinical Research Site
    Tampa, Florida 33614, United States
  • Clinical Research Site
    Tampa, Florida 33634, United States
  • Clinical Research Site
    Braintree, Massachusetts 02184, United States
  • Clinical Research Site
    Brooklyn, New York 11229, United States
  • Clinical Research Site
    Charlotte, North Carolina 28211, United States
  • Clinical Research Site
    Mesquite, Texas 75149, United States
  • Clinical Research Site
    Arlington, Virginia 22205, United States
  • Clinical Research Site
    San Juan, 00918, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Feb 2025, 2 months.

Results were first posted in Jun 2026, 1 year 4 months after primary completion. A results delay was requested in Feb 2026.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Dec 16, 2024
StartActual
Nov 21, 2024
Primary completionActual
Feb 17, 2025
CompletionActual
Apr 25, 2025
Results delay requested
Feb 17, 2026
Results first posted
Jun 25, 2026
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06736509
Responsible party
Sponsor
First posted
Dec 16, 2024
Start date
Nov 21, 2024
Primary completion
Feb 17, 2025
Completion
Apr 25, 2025
Results posted
Jun 25, 2026
Last update
Jun 25, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion